{"analyses":[{"ciLowerLimit":"-10","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"-5"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.9","upperLimit":"19.5","value":"16.0"},{"groupId":"OG001","lowerLimit":"17.6","upperLimit":"24.8","value":"21.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"507"},{"groupId":"OG001","value":"509"}],"units":"Participants"}],"description":"An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"NUMBER","populationDescription":"The safety population includes all participants with available data post baseline, analyzed as treated.","reportingStatus":"POSTED","timeFrame":"Day 1 through Day 29","title":"Percentage of Participants Reporting Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}